AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02872116
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT02872116
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT01792700
Drug: tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03901144
Drug: 2% urea/20% glycerol cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing cream for topical application
Trial: NCT03901144
Drug: Miniderm® 20% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing cream for topical application
Trial: NCT03901144
Drug: Diprobase® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream for topical application
Trial: NCT02952365
Drug: Tissue sealant
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of tissue sealant on eyes undergoing LASIK enhancement
Trial: NCT00128895
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine 2 mg/kg oral once daily, duration according to arm
Trial: NCT03413124
Drug: MGL-3196 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGL-3196 in Tablet form
Trial: NCT02852681
Drug: 15 mg E4/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
Trial: NCT03413124
Drug: MGL-3196 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGL-3196 in Capsule form
Trial: NCT01329627
Drug: Paclitaxel/doxorubicin/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Trial: NCT00736853
Drug: Tramadol Hydrochloride Plus Acetaminophen (Open-Label)
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
Trial: NCT00736853
Drug: Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose \[number of tablets\] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
Trial: NCT01329627
Drug: Paclitaxel/doxorubicin/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Trial: NCT00551876
Drug: Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01528930
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg, once daily for 2 years
Trial: NCT02202395
Drug: LTS 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use LTS 0.5mg/d
Trial: NCT02202395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use placebo once daily
Trial: NCT01484210
Drug: Elpenhaler active - Diskus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
Trial: NCT02202239
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
Trial: NCT02202239
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be injected continuously during maintenance of anesthesia.
Trial: NCT06051786
Drug: Dymista™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dymista™ is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid. Dymista™ is administered intranasally and is used to treat Allergic Rhinitis (AR).
Trial: NCT02763839
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Trial: NCT02763839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
Trial: NCT02763839
Drug: Sinemet 25/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
Trial: NCT00431626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before and after treatment of TURP
Trial: NCT01104896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
Trial: NCT00395603
Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01903798
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroid
Trial: NCT00485017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules daily in a.m. and in p.m. for 24 weeks
Trial: NCT02899936
Drug: 3 drug dose - IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Trial: NCT01276262
Drug: Microgynon® 30 (Oral contraceptive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, repeated doses
Trial: NCT01276262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets BID, repeated doses for 21 days
Trial: NCT00174902
Drug: inderal (drug), acetylsalicylic acid (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00702845
Drug: recFSH (follitropin beta)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU recFSH SC injection
Trial: NCT00702845
Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Trial: NCT00461747
Drug: VBMCP/VBAD/Velcade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20.
Trial: NCT02139943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule will be taken orally, before the first meal of the day.
Trial: NCT04120597
Drug: Zishen Qingre Lishi Huayu Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Trial: NCT04120597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Trial: NCT02113072
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
Trial: NCT02113072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
Trial: NCT01041417
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection
Trial: NCT03087513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
Trial: NCT02299375
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
Trial: NCT02047981
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Trial: NCT02047981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
Trial: NCT03077542
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: conditioning regimen
Trial: NCT02569866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing placebo/500mg
Trial: NCT01333293
Drug: injections
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections
Trial: NCT01943812
Drug: Estradiol and progeterone
RxNorm normalized name: medroxyprogesterone and estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol and progesterone
Trial: NCT01713946
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Trial: NCT01713946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
Trial: NCT01713946
Drug: Antiepileptic drug (1 to 3 only)
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
Trial: NCT00871871
Drug: Comparator: Placebo to HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
Trial: NCT00871871
Drug: Comparator: Placebo to ISMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
Trial: NCT01467011
Drug: Enteric-coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1440mg/day for 6 months posttransplant
Trial: NCT01875159
Drug: Caffeine citrate 6 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
Trial: NCT00908453
Drug: fosphenytoin
RxNorm normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
Trial: NCT04480840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02219646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two tablets daily for 6 months
Trial: NCT00866203
Drug: HDS vs ProMECE/CytaBOM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00032669
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03707509
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum 6 cycles for combined therapy.
Trial: NCT05241509
Drug: Cymbopogon citratus (lemongrass) oil gel
RxNorm normalized name: CYMBOPOGON CITRATUS LEAF OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
Trial: NCT04398511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges after breakfast, lunch and dinner for 21 days.
Trial: NCT00637065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tables - identical to active drug but without the active ingredient -
Trial: NCT00823186
Drug: Phyxol(Paclitaxel)
RxNorm normalized name: phytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine
Trial: NCT00629863
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00527735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
Trial: NCT01545726
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 was supplied as capsules for oral administration.
Trial: NCT01545726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as capsules for oral administration.
Trial: NCT02122679
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03014947
Drug: MSB11022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
Trial: NCT03014947
Drug: US-licensed Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
Trial: NCT03014947
Drug: EU-approved Humira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
Trial: NCT01094613
Drug: Delayed Release 6 mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.
Trial: NCT01094613
Drug: 6 Mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
Trial: NCT02431988
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
Trial: NCT02211053
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg IV bolus + 10 mg/h infusion
Trial: NCT02211053
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01687361
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule, 2x/day for 14 days
Trial: NCT03902691
Drug: ESPO
RxNorm normalized name: Espotabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
Trial: NCT00671034
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00671034
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00671034
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00671034
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, IT, or PO
Trial: NCT00330759
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
Trial: NCT00997035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment.
Trial: NCT02863614
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02863614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00930891
Drug: Standard Chemotherapy (PCDE or PE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles
Trial: NCT00930891
Drug: Experimental Treatment (PCDE or PE + bevacizumab)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression